The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.
 
Jose Pablo Leone
Research Funding - Kazia Therapeutics (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Carlos Teodoro Vallejo
No Relationships to Disclose
 
Michael J. Hassett
No Relationships to Disclose
 
Julieta Leone
No Relationships to Disclose
 
Rachel A. Freedman
Research Funding - Eisai (Inst); Puma Biotechnology (Inst)
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Celldex; Eisai; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Bernardo Amadeo Leone
No Relationships to Disclose
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; InfiniteMD; Jounce Therapeutics; Jounce Therapeutics; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)